Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Hemoglobin, Cerebral Oxygenation, Congenital Heart Disease
Interventions: Noninvasive hemoglobin monitoring; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Days to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coagulopathy
Interventions: Thromboelastography (TEG 6S); Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 3 Months to 18 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Kidney Failure, Kidney Transplant; Complications, Chimera
Interventions: Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine, Cyclophosphamide, Rituximab, Siplizumab; Other · Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Head and Neck Cancer
Interventions: Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy), Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site)., Nivolumab 3 mg/kg IV q2 weeks, Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).; Radiation · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Esophageal Cancer
Interventions: wireless pulse oximeter (Wipox); Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Bile Duct Stricture, Choledocholithiasis
Interventions: Blood draw for culture; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Ovarian Cancer
Interventions: flutamide; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 83 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: HLH - Hypoplastic Left Heart Syndrome, DORV, DILV - Double Inlet Left Ventricle, Mitral Atresia, Tricuspid Atresia, Unbalanced AV Canal, Single-ventricle, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases
Interventions: Tissue Engineered Vascular Grafts; Combination Product
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
Interventions: Not listed
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 2
States / cities: Metairie, Louisiana • New Orleans, Louisiana

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Electronic Health Record Review, Interview, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 2,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 259
States / cities: Jonesboro, Arkansas • Anaheim, California • Antioch, California + 203 more

Conditions: Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, Uterine Cervical Cancer
Interventions: Radiation Treatment With or Without Chemotherapy, Blood Sample Collection, HPV Genotyping (HPV DNA Test), Testing Archival Tumor Tissue, Physical Exam, Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan); Radiation · Other · Diagnostic Test
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Pancreatic Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Cancer
Interventions: Germline genetic testing; Diagnostic Test
Lead sponsor: Invitae Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Fertility
Interventions: Not listed
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Hialeah, Florida • Miami, Florida

Conditions: Shoulder Pain
Interventions: Indirect MRA of shoulder, Gadopentetate Dimeglumine; Procedure · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Age-related Macular Degeneration
Interventions: Ranibizumab 0.5mg; Drug
Lead sponsor: Leonard Feiner, MD, PhD; Other
Eligibility: 50 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Teaneck, New Jersey • Vauxhall, New Jersey

Conditions: Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 25
States / cities: Washington D.C., District of Columbia • Gainesville, Florida • Miami, Florida + 19 more

Conditions: Hemophilia A
Interventions: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 11 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 9 more

Conditions: Asthma, COPD, Chronic Obstructive Pulmonary Disease
Interventions: Blood draw, Urine, Lung function measurements, Fractional Exhaled Nitric Oxide (FENO); Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 12,255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 40
States / cities: Loma Linda, California • Long Beach, California • Roseville, California + 33 more

Conditions: Hemophilia A, Prophylaxis of Bleeding
Interventions: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).; Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more

Conditions: Primary Graft Failure
Interventions: FLT imaging and TK1 blood measurements; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 4 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 1 more

Conditions: Blood Loss, Surgical
Interventions: Fibrin Sealant 2 (FS2), Oxidized Regenerated Cellulose (Surgicel); Drug · Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: Not listed
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 16
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 12 more

Conditions: Multiple Sclerosis
Interventions: Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: Female only
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Aurora, Colorado • Durham, North Carolina

Conditions: Shoulder Pain, Injury of Shoulder Region, Disorder of Shoulder, Disorder of Rotator Cuff, Disorder of Tendon of Biceps
Interventions: Dexamethasone, Bupivacaine; Drug
Lead sponsor: Lifespan; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Newport, Rhode Island

Conditions: Burn Injury
Interventions: Albumin Human; Drug
Lead sponsor: American Burn Association; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Phoenix, Arizona • Sacramento, California • Torrance, California + 21 more

Search by objective public record fields.

Observational Data Collection for Blood Hemoglobin Algorithm Validation in Pediatrics

Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients

Delayed Tolerance Through Mixed Chimerism

Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer

Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy

Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).

Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts

Transplacental Transmission of RSV (TTRSV)

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Detecting HPV DNA in Anal and Cervical Cancers

ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing

Fertility in Healthy Premenopausal Women

A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

BAX 855 Pediatric Study

Observational Study of Obstructive Lung Disease (NOVELTY)

Prophylaxis Regimen for Hemophilia A Patients

REVEAL Biomarkers of Engraftment After Alternative Donor HSCT

Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block

The Acute Burn ResUscitation Multicenter Prospective Trial